Prevention of Catheter-Related Bloodstream Infections in Patients on Hemodialysis by Dulce Barbosa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Prevention of Catheter-Related Bloodstream 
Infections in Patients on Hemodialysis 
Dulce Barbosa, Mônica Taminato, Dayana Fram,  
Cibele Grothe and Angélica Belasco 
Federal University of São Paulo/UNIFESP 
Brazil 
1. Introduction 
Fourteen percent of deaths among patients with endstage kidney disease (ESKD) are due to 
infections, preceded only by cardiovascular diseases (USRDS,2006). According to The 
United States Renal Data System (USRDS), the number of patients receiving hemodialysis in 
the United States of America (USA) was 328,000 in 2006(USRDS,2008). Secondary to 
multiple defects in the ability to kill bacteria, infectious complications are more frequent in 
the Chronic Kidney Disease (CKD) and dialysis populations. (USRDS,2010). 
Data from Brazilian Society of Nephrology reported that the number of patients on dialysis 
treatment in Brazil was 77.589 in 2009 and 90.8% of those patients were receiving 
hemodialysis (SBN,2010). The estimated prevalence and incidence rates of chronic renal 
failure on maintenance dialysis were 405 and 144 patients per million population, 
respectively. The estimated number of new patients starting dialysis program in 2010 was 
49,077. The annual gross mortality rate was 17.1%. For prevalent patients, 39.9% were aged 
60 years or older, 89.6% were on hemodialysis and 10.4% on peritoneal dialysis, 30,419 
(39.2%) were on a waiting list of  renal transplant, 27% were diabetics, 37.9% had serum 
phosphorus > 5.5 mg/dL and 42.8% hemoglobin < 11 g/dL. A venous catheter was the 
vascular access for 12.4% of the hemodialysis patients. 
CVC (CVC) as vascular access are considered inferior to other means of vascular access with 
2006 K/DOQI guidelines recommending less than 10% prevalence rate. However, despite 
these recommendations the Dialysis Outcomes and Practice Patterns Study (DOPPS II), 
reports that 46% to 70% of European and Canadian ESKD patients commencing 
maintenance haemodialysis do so via a CVC. This dependence on CVC is also reflected in 
the prevalence rates which range from 18% (Europe) to 34% (Canada) (Mendelssohn DC 
2006 ). This over reliance on catheters may be attributed to late referrals to nephrologists, 
delay in access formation, lack of sufficient time for an AVF to mature or an ever increasing 
older ESKD population who experience higher rates of vascular disease and diabetes 
resulting in an inadequate vasculature for AVF formation (Butterly DW 2001 ; Letourneau I 
2003 ; Mendelssohn DC 2006 ). 
Data from the USA National Healthcare Safety Network demonstrated that bloodstream 
infection rates in 2006 varied according to the site of vascular access: 0.5% arteriovenous 
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fistula (AVF), 0.9% AV grafts, 4.2% long-term central venous catheter and 27.1% short-term 
central venous catheter per month, respectively.  
Chronic kidney disease (CKD) is a syndrome caused by many diseases that have in 
common the progressive reduction of glomerular filtration. Regardless of the initial insult 
caused by the underlying disease, the lesion progresses to glomerulosclerosis and 
interstitial fibrosis, resulting in established chronic kidney disease (ECKD). The ECKD 
treatment depends on the evolution of the disease and may be conservative with 
medication use, diet and fluid restriction, when such treatment becomes insufficient, you 
need to start dialysis to replace, in part, the kidney's function, or even apply to a kidney 
transplant (Mason J et al, 2008). 
Conservative treatment aims to help reduce the rate of progression of the renal disease, 
using the dietary guidelines that aim to promote adequate nutritional status, metabolic 
control and uremic symptoms (20), with the improvement in organ dysfunction and 
comorbid conditions such as infection, contributing to better outcomes related to dialysis 
and transplantation (Klevens RM et al, 2008). 
Despite advances in dialysis mortality remains high in ECKD. The infection continues to be 
a major cause of morbidity and the second most frequent cause of mortality (14%), preceded 
only by cardiovascular events as the first cause of death (Klevens RM et al, 2008).  
Most microorganisms detected in the blood culture were considered to be a skin 
contaminant coagulase-negative Staphylococcus. Forty two percent (42%) of Staphylococcus 
aureus were resistant to methicillin and 39% of Enterococcus spp were resistant to 
vancomycin (Klevens et al,2008). Patients receiving hemodialysis have high risk for infection 
due to immunosuppression caused by ESKD, comorbidities, inadequate diet and the need 
for maintaining the venous access for long periods. In dialysis clinics many patients are 
submitted to this procedure at the same time, leading to the dissemination of 
microorganisms through direct or indirect contact with the devices, equipment, 
contaminated surfaces or the hands of health professionals. 
In a study conducted at the Federal University of São Paulo (UNIFESP) it was found an 
incidence of infection of the bloodstream of 61% among patients with ESKD in use of central 
venous catheter associated with a mortality rate of 29% ( Grothe C et al, 2009). 
American data show that the main agents of bloodstream infections in hemodialysis patients 
were methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus coagulase negative 
(SCN) and vancomycin-resistant Enterococcus spp (VRE) (Klevens RM, 2008). 
S. aureus is an important etiologic agent of both community-acquired infections and 
healthcare associated infections (HAI). In community-acquired infections are responsible 
for infections of skin and soft tissues, but is also responsible for invasive infections such as 
pyomyositis, osteomyelitis, necrotizing fasciitis, pneumonia and severe sepsis (King MD 
et al, 2006; Bocchini CE et al 2006; PV Adem et al , 2005). This agent is an important 
colonizer of the skin and mucous membranes. Although many sites of the human body 
can be colonized, nasal colonization is the most common. Studies show that 
approximately 20% of health professionals have persistent colonization and 80% 
intermittent colonization by this microorganism, nasal colonization is the biggest risk 
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factor for the development of most endogenous infections (Van Belkum A et al, 2009 ; 
Wertheim HF et al, 2004; Von Eiff C et al, 2001). 
Following the acquisition of MRSA colonization during hospitalization, patients with 
chronic renal failure on conservative treatment may persist as carriers for prolonged periods 
even after discharge from hospital and readmittance, may reintroduce the bacteria in the 
hospital (Roberts S et al, 2004) 
The risk of transmission occurs most often because the patient is not identified as a carrier. A 
retrospective analysis that used information from hospital patients for eight years evaluated 
the risk of acquiring MRSA in patients who shared the same room with other hospital patients 
colonized with MRSA, unidentified. The study found a 13% incidence of infection by the same 
strain of MRSA among colonized patients (Moore C et al, 2008). Another study that evaluated 
the prevalence of MRSA on admission identified that 49% of patients would not have been 
identified without screening on admission (VCC Cheng et al, 2008). 
Faced with complications that occurred due to infection in patients on dialysis treatment, 
Barbosa et al (D Barbosa et al, 2004; MCS Freitas et al, 2006) assessed the prevalence of 
colonization by vancomycin-resistant Enterococcus (VRE) in 300 patients in program 
dialysis and 280 transplant recipients treated in this service. It was found a prevalence 
rate of 14.5% in dialysis patients and 14% in renal transplanted patients, which proves to 
be quite high in relation to the rate documented in American services, which is around 
7% (Tokars JI et al, 2000). The molecular typing of these samples was recently performed 
and it made possible the important detection of cross-transmission of VRE among 
patients treated at the Department of Dialysis and Transplantation of UNIFESP, and  
Fram et al observed the occurrence of vancomycin-resistant Enterococcus (VRE) cross-
transmission between two patient groups (long-term dialysis and kidney transplant 
patients) Fram D et al, 2010.  
In Europe and the United States the increase in infections caused by VRE in patients with 
ESKD have contributed to an increased morbidity and mortality in this patients population, 
which has generated a great concern in the nephrology services (Perencevich EM et al, 2004). 
Data from the National Healthcare Safety Network show that VRE was isolated in 26% of 
dialisys patients' blood cultures (Rom Klevens, 2008). 
In the 90s, there was a significant increase in the prevalence of VRE infection in hospitals, 
particularly among immunosuppressed patients, such as those with chronic diseases, 
infectious diseases and renal transplants (Brady JP et al, 1998). Currently, VRE is between 
the second and third most frequent cause in the IRAS, due to its rapid spread, high 
associated mortality and limited treatment options, besides the possibility of transfer of the 
vanA resistance gene to other virulent organisms and more prevalent as the S . aureus 
(Chang S et al, 2003; & Salgado CD Farr BM, 2003). 
The glycopeptide resistance may be mediated by several genes, vanA, vanB, vanC, vanD, 
vanE, vanG and vanL. Resistance mediated by mobile elements, called plasmids, may be 
transferred from one strain of VRE to another (Werner G et al, 2008; Arthur M, 1993) 
The increased risk of VRE colonization and infection has been associated with the 
indiscriminate use of antibiotics, prolonged hospital stay, underlying diseases, 
transplantation, invasive treatments such as intra-abdominal surgery, presence of central 
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venous catheterization and proximity to colonized patients. Studies done in the UNIFESP's 
nephrology service demonstrated the presence of VRE in dialysis patients and kidney 
transplantation. Among dialysis patients, the colonization prevalence was 14.5% and the 
identified risk factors were: dialysis type (hemodialysis), number of hospitalizations and 
length of hospital stay. Similar rate was found among patients undergoing renal 
transplantation, where the prevalence was 14%, although no risk factor was identified 
(Barbosa D et al, 2004; MCS Freitas et al, 2006). 
Considering the emergence of new microorganisms, Klebsiella pneumoniae producing 
carbapenemases (KPC) has been highlighted as an important pathogen in healthcare 
related infections. Due to the great ability to spread and limited therapeutic options, the 
introduction of surveillance of this pathogen in the study group is necessary. According to 
a recent study by Ji-Young Rhee (2010),  the isolation of bacteria K. pneumoniae producing 
carbapenemases (KPC) in hemodialysis patients with chronic renal failure demonstrated 
that the infection caused by multidrug-resistant pathogen that affected the patient's 
prognosis. Another study in Chicago showed that the implementation of a bundle that 
includes: surveillance cultures, team education, contact precautions, chlorhexidine 
bathing and environment cleaning greatly reduced the horizontal transmission of this 
pathogen (Mimoz O, 2007). 
Microbial resistance should be considered because patients on dialysis treatment are often 
hospitalized and exposed to multi-resistant microorganisms and to broadspectrum 
antimicrobial therapy. (Klevens et al, 2008; Fram et al, 2010; Horl Wh 1999;Descamps-
Latscha B & Herbelin A, 1993; MMWR,2001). On the one hand, the quality of dialysis and 
thus patients. well being and survival depend on the venous access; on the other hand, this 
is considered the major risk factor for infection and especially bacteremia in this group of 
patients(Mangini et al, 2005). In a study performed at Universidade Federal de São Paulo, 
61% of patients with ESKD using central venous catheter presented bacteremia. Risk factors 
for bacteremia were: catheter insertion in the subclavian vein, duration of catheter use and 
the hospitalization period. The mortality rate in these patients was 29% and for patients who 
developed endocarditis it was 55.5%(Groethe C et al, 2010). As this population is exposed to 
a high infection risk which can be prevented in most cases by health professionals, a 
systematic review of literature was performed to establish standard measures to prevent 
catheter associated infections in hemodialysis patients. 
1.2 Epidemiology 
Twenty months of epidemiological surveillance data in the USA demonstrated that the risk 
for bacteremia was 32 times higher when short-term venous catheter was used, and 19 times 
higher when long-term venous catheter was used compared to the use of arteriovenous 
fistula (AVF). Similar data were observed in a study conducted in 11 dialysis centers in 
Canada (George A et al, 2006). A prospective survey with 35,000 randomized patients 
between the years of 1996 and 2007 treated in about 300 dialysis units in 12 countries 
demonstrated a great variation on AVF utilization. AVF use declined in elderly, obese, 
diabetic and patients with cardiovascular diseases or recurrent cellulitis. Considering the 
high mortality caused by the use of catheters, the best option for these patients is AV graft. 
However, in some countries there was an increase in catheter use and a proportional 
decrease in the use of AV grafts in patients with the characteristics mentioned (LoboRD et 
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al, 2005). Measures to prevent catheter associated infections in hemodialysis patients must 
be considered taking into account the reduction in the use of central venous catheter (CVC), 
giving priority to the use of AVF whenever possible. However, in patients with impaired 
vessels, obesity and diabetes, where access through AVF or graft can be difficult, long-term 
CVC use is recommended(MMWR, 2001). 
2. Methods 
The present study was carried out through a review of the literature encompassing the 
issue of preventing catheter-associated bloodstream infections in hemodialysis patients. 
Studies published from 1990 to 2011 have been selected through electronic search in the 
following databases: Cochrane Library,CINAHL, WEB OF SCIENCE, Medline, SciELO, 
Embase, Lilacs, works presented in congresses, reviews and guidelines. The search strategy 
used for Medline presented the following steps: .Catheterization, Central Venous. [Mesh] 
AND .Infection. [Mesh]) AND .Renal Dialysis. [Mesh]) AND .Renal Dialysis/education. 
[Mesh] AND .Infection Control. [Mesh]. To select articles, two independent reviewers 
assessed the titles and abstracts of the publications found. All studies in the issue meeting 
the criteria for review have been included regardless of the language or design. 
Photocopies of the articles have been obtained and a standard form has been used to 
extract data. 
3. Results 
Two hundred and ninety three articles were found according to the used descriptors, 50 of 
them were literature reviews. After a previous selection, we included some studies that met 
the inclusion criteria were selected according to the assessment of the two independent 
reviewers. Among the studies analyzed we included (chart 1) systematic reviews, 
prospective cohorts, experimental study, meta-analysis review, controlled randomized 
clinical essays, cross-sectional randomized clinical trial and guidelines.  
It was clear that surveillance is the essential issue for an infection control program and also 
for improving quality of care. A prospective study carried out in London between 2002 and 
2004 with 112 patients (3418 patients per month) demonstrated reduction in bacteremia rate 
from 6.2% to 2.0% per month, reduction in hospitalizations due to bacteremia from 4.0% to 
1.4% per month and also a significant downward trend was seen in bacteremia rates and 
antibiotic usage after the introduction of a surveillance scheme with patients. risk 
stratification, definition of denominators, type of access performed by physicians and nurses 
from the service, team training, preventive measures of infections, dissemination of data and 
use of results to optimize the actions introduced (George A et al, 2006). The training and 
education of health professionals, patients and care givers is recommended by the Center 
for Disease Control and Prevention (CDC) to prevent dialysis infections and must be 
compatible with the available knowledge from the personnel involved(9). A study conducted 
in a university hospital from São Paulo demonstrated 40% reduction in catheter-associated 
bloodstream infections (CABSI) after the implementation of an educational intervention 
with staff members (Lobo RD et al, 2005) 
There are some standard precautions based on strategies to prevent transmission of 
infections that health professionals must use in patients. care: hand washing before and after  
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the contact, use of gloves, masks, protection glasses and laboratory coats when there is risk 
of contact with biological material, be careful with sharp-edged and hollow-pointed devices, 
environmental cleaning, adequate use of materials and equipments and health professionals 
immunization. When patients present suspicion or confirmation of a more severe infection, 
additional measures must be taken in addition to those mentioned above (Ethier J et al 
2008). According to national and international recommendations, catheter insertion has to be 
conducted under sterile conditions and maximum barrier: masks, laboratory coats, gloves 
and sterile drapes (Descamps-Latscha B & Herbelin A, 1993; MMWR 2001; O.Grady NP et 
al, 2002). Alcoholic chlorhexidine 2% (drug of choice) or polyvinylpyrrolidone-iodine 
solution (PVP-I) 10% has to be used for skin antisepsis before catheter insertion and before 
dressing changes (MMWR, 2001; Mimoz O et al, 2007). 
A CVC can be non-tunnelled or tunnelled. A non-tunnelled catheter - sometimes referred 
to in the literature as non-cuffed, temporary, short-term or acute - is intended for short-
term haemodialysis use. On the other hand tunnelled catheters - also known as cuffed, 
chronic, long-term or permanent catheters - are generally used when patients require 
more than two to three weeks haemodialysis (Frankel, 2006). However, the reported use 
of these different catheters suggest that tunnelled catheters have been used for periods of 
short duration and, although not recommended, non-tunnelled catheters have been used 
for periods of long duration (months or years) (Ash SR, 2001; KDOQI 2006; Oliver MJ 
2001; Ponikvar R, 2005). 
A Cochrane systematic review with meta-analysis, published in 2003 compared the use of 
gauze and micropore film versus sterile transparent semipermeable polyurethane (Opsite ® 
(Smith & Nephew Healthcare Ltd), Tegaderm ® (3M) and Opsite IV3000 ®) to cover the 
catheter central venous . The transparent film covers so classified as highly permeable and 
permeable polyurethane polyurethane. The outcomes analyzed in this review were: 
catheter-related sepsis, infection at the catheter insertion site and colonization of catheter 
between the different types of coverage, but there was no statistical difference in any 
outcome analysis. One of the observations made by the plaintiff was an insufficient number 
of randomized clinical trials that could be included in the study ( Gillies D et al, 2003) 
A randomized study(Sesso R et al, 1998) highlighted that use of chlorhexidine before 
catheter insertion and during dressing changes is associated with less colonization and 
occurrence of CABSI when compared to the use of alcoholic PVP-I. Gauze or sterile 
transparent film are recommended to dress the site of catheter insertion. After bathing or 
showering it is important to inspect the insertion site, protecting it and replacing the 
catheter-site dressing when it becomes damp, loosened, or soiled (Descmaps-Latscha B & 
Herbelin A,1993; MMWR 2001; Ethier et al, 2008). A study (Sesso R et al 1998) demonstrated 
that mupirocin use in the catheter insertion site reduces significantly the risk of S aureus 
colonization and bacteremia. The same result was obtained in a study carried out in 
Australia ( Johnson DW et al 2.002).  
The meta-analysis of a profhylatic use of Mupirocin in central venous catheter for 
hemodialysis indicates that the use of topical mupirocin has been effective to reduce 
episodes of infections among patients increasing the usage time of the catheter in addition to 
significantly reducing the infections by S aureus, the most prevalent in this population 
(Taminato M et al, 2011).  
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Other systematic review ( McCann M & Moore ZEH, 2008) shws that topical antimicrobial 
ointments compared to no ointment or placebo had a significant favourable effect on 
catheter removal due to infection caused by all types of organisms ( RR 0.35, 95% CI 0.25 to 
0.50). Catheter removal due to S. aureus was significantly reduced by topical antimicrobial.  
However, the emergence of resistant strains must be considered as demonstrated in a 
Spanish study where pandemia of methicillin-resistant Staphylococcus aureus was associated 
to high-level mupirocin resistance (Johnson et al, 2002; Perez-Roth E et al, 2006).  
Another prevention strategy is the use of gentamicin, cephalosporin or vancomycin lock 
solution, taking into account the possibility of the emergence of resistant microorganisms 
when vancomycin is used (Bleyer AJ, 2007; Safdar N & Maki DG, 2006).   
The study Al-Kwiesh & Abdulla Khalaf, showed that the administration of vancomycin 
catheter lock via intralumenal was superior compared to the peripheral intravenous 
administration, where the results showed that the experimental group of 28 patients that 
used the vancomycin catheter lock had only one (3%) catheter removal, in contrast, the 
control group of 39 patients that had peripheral intravenous antibiotics had 22 (56%) 
catheter removals. 
In a meta-analysis, authors demonstrated that in highrisk patients treated with long-term 
catheters the use of vancomycin lock solution reduces the risk of bacteremia(Safdar N & 
Maki DG, 2006). CDC does not recommend the regular use of antimicrobial lock solution to 
prevent bloodstream infection. The use is recommended only in special circumstances (e.g. 
patient with a long-term catheter or patients with clinical data of recurrent infections despite 
optimal maximal adherence to aseptic technique (O´Grady et al, 2002). 
4. Conclusion 
The authors conducted extensive review to suggest that catheter-associated bloodstream 
infection can be reduced when prevention measures are adequately taken they are: proper 
choice of insertion site, local antisepsis, personnel appropriate attire, infection surveillance, 
care and maintenance of the catheter or remove as well as the use of new technologies. 
Topical mupirocin ointment significantly reduced the risk of S. aureus exit site infection and 
catheter-related bacteraemia. The risk of catheter removal and episodes of hospitalisation 
due to S. aureus were also significantly reduced in those patients who used topical 
mupirocin ointment. Taking into account that this is a population at high risk for infection, 
the emergence of multi-resistant microorganisms must be considered, and if a severe case 
occurs, additional prevention measures must be taken to avoid an outbreak in this 
population.  All personnel involved in the process of catheter insertion, maintenance and 
removal must be aware of the importance of excellent care for infection prevention therefore 
this chapter may contribute to infection control book. 
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